Skip to main content
SpringerLink
Log in

Cytotoxicity of ZIF-8@APTES-MS on murine melanoma cells

  • Materials for life sciences
  • Published:
Journal of Materials Science Aims and scope Submit manuscript

Abstract

In this research, ZIF-8 was synthesized and subsequently functionalized by 3-aminopropyltrimethoxysilane (APTES) as a carrier (ZIF-8@APTES) for montelukast sodium (MS). One of the aggressive cancers with a high fatality rate is melanoma. This study aimed to determine the potential cytotoxic effects of montelukast sodium (MS) on the B16F10 murine melanoma cell line as well as the therapeutic effects of MS combined with ZIF-8@APTES as a carrier. B16F10 cells were treated with different doses of ZIF-8@APTES-MS for 24, 48, and 72 h, and then the cytotoxic effect and antioxidant activity of these treatments were studied. Results indicated that after 48 and 72 h, B16F10 cell proliferation was reduced in a dose-dependent manner by MS and/or ZIF-8@APTES-MS. When MS is combined with ZIF-8@APTES, the IC50 concentration is lower than when MS is used alone. Furthermore, receiving 32 μg/ml ZIF-8@APTES-MS after 72 h significantly improved the total antioxidant activity (TAC) of B16F10 cells. In this research, the treatment of melanoma cells with MS and ZIF-8@APTES-MS was investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Dhanyamraju PK, Patel TN (2022) Melanoma therapeutics: a literature review. J Biomed Res 36(2):77–97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Eddy K, Shah R, Chen S (2021) Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. Front Oncol 10:626129

    Article  PubMed  PubMed Central  Google Scholar 

  3. Maio M (2012) Melanoma as a model tumour for immuno-oncology. Ann Oncol 23(Suppl 8):10-viii10- viii14

    Article  Google Scholar 

  4. Leonardi GC et al (2018) Cutaneous melanoma: from pathogenesis to therapy. Int J Oncol 52(4):1071–1080

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Sahoo BM et al (2021) Drug repurposing strategy (DRS): emerging approach to identify potential therapeutics for treatment of novel coronavirus infection. Front Mol Biosci 8:628144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Tian W et al (2020) Leukotrienes in tumor-associated inflammation. Front Pharmacol 11:1289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Aigner L et al (2020) The leukotriene receptor antagonist montelukast as a potential COVID-19 therapeutic. Front Mol Biosci 7:610132

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. El-Sisi AE-DE et al (2015) Role of cysteinyl leukotriene receptor-1 antagonists in treatment of experimentally induced mammary tumor: does montelukast modulate antitumor and immunosuppressant effects of doxorubicin? Toxicol Ind Health 31(11):1024–1036

    Article  CAS  PubMed  Google Scholar 

  9. Slater K et al (2020) High cysteinyl leukotriene receptor 1 expression correlates with poor survival of uveal melanoma patients and cognate antagonist drugs modulate the growth, cancer secretome, and metabolism of uveal melanoma cells. Cancers (Basel) 12(10):2950

    Article  CAS  PubMed  Google Scholar 

  10. Zhu L et al (2017) Cysteinyl leukotrienes as novel host factors facilitating Cryptococcus neoformans penetration into the brain. Cell Microbiol 19(3):e12661

    Article  Google Scholar 

  11. Piromkraipak P et al (2018) Cysteinyl leukotriene receptor antagonists inhibit migration, invasion, and expression of MMP-2/9 in human glioblastoma. Cell Mol Neurobiol 38:559–573

    Article  CAS  PubMed  Google Scholar 

  12. Tsai M-J et al (2017) Montelukast induces apoptosis-inducing factor-mediated cell death of lung cancer cells. Int J Mol Sci 18(7):1353

    Article  PubMed  PubMed Central  Google Scholar 

  13. Yurtdaş-Kirimlioğlu G, Görgülü Ş (2019) Design and characterization of montelukast sodium loaded Kollidon® SR nanoparticles and evaluation of release kinetics and cytotoxicity potential. Lat Am J Pharm 38(7):1350–1360

    Google Scholar 

  14. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5(3):161–171

    Article  CAS  PubMed  Google Scholar 

  15. Alrushaid N et al (2023) Nanotechnology in cancer diagnosis and treatment. Pharmaceutics 15(3):1025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Rabiee N et al (2022) Green metal-organic frameworks (MOFs) for biomedical applications. Microporous Mesoporous Mater 335:111670

    Article  CAS  Google Scholar 

  17. Yang J et al (2023) Multifunctional metal-organic framework (MOF)-based nanoplatforms for cancer therapy: from single to combination therapy. Theranostics 13(1):295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Raptopoulou CP (2021) Metal-organic frameworks: Synthetic methods and potential applications. Materials 14(2):310

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wang Q et al (2020) Synthesis and modification of ZIF-8 and its application in drug delivery and tumor therapy. RSC Adv 10(62):37600–37620

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ke Q et al (2023) Sulfonated vitamin K3 mediated bimetallic metal-organic framework for multistage augmented cancer therapy. J Colloid Interface Sci 654:224–234

    Article  PubMed  Google Scholar 

  21. Shi L et al (2020) In situ biomimetic mineralization on ZIF-8 for smart drug delivery. ACS Biomater Sci Eng 6(8):4595–4603

    Article  CAS  PubMed  Google Scholar 

  22. Wang H et al (2019) One-pot synthesis of poly (ethylene glycol) modified zeolitic imidazolate framework-8 nanoparticles: size control, surface modification and drug encapsulation. Colloids Surf, A 568:224–230

    Article  CAS  Google Scholar 

  23. Zhou Z et al (2023) Pore space partition approach of ZIF-8 for pH responsive codelivery of ursolic acid and 5-fluorouracil. ACS Mater Lett 5(2):466–472

    Article  CAS  Google Scholar 

  24. Feng S et al (2021) Zeolitic imidazolate framework-8 (ZIF-8) for drug delivery: a critical review. Front Chem Sci Eng 15(2):221–237

    Article  MathSciNet  CAS  Google Scholar 

  25. Ding B et al (2023) ZIF-8 Nanoparticles evoke pyroptosis for high-efficiency cancer immunotherapy. Angew Chem 135(10):e202215307

    Article  Google Scholar 

  26. Vasconcelos IB et al (2012) Cytotoxicity and slow release of the anti-cancer drug doxorubicin from ZIF-8. RSC Adv 2(25):9437–9442

    Article  ADS  CAS  Google Scholar 

  27. Ettlinger R et al (2019) Zeolitic imidazolate framework-8 as pH-Sensitive nanocarrier for “arsenic trioxide” drug delivery. Chem-A Eur J 25(57):13189–13196

    Article  CAS  Google Scholar 

  28. Abdi J et al (2017) Synthesis of amine-modified zeolitic imidazolate framework-8, ultrasound-assisted dye removal and modeling. Ultrason Sonochem 39:550–564

    Article  CAS  PubMed  Google Scholar 

  29. Chen Y, Zhang J, Wei S (2023) Montelukast inhibits lung cancer cell migration by suppressing cysteinyl leukotriene receptor 1 expression in vitro. Curr Pharm Biotechnol 24(10):1335–1342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Tang C et al (2018) Montelukast inhibits hypoxia inducible factor-1α translation in prostate cancer cells. Cancer Biol Ther 19(8):715–721

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kani SNM, Samadi-Maybodi A, Najafzadehvarzi H (2023) Functionalized ZIF-8 with aminopropyltrimethoxysilane as montelukast sodium carrier for medical application. Chem Select 8(37):e202302774

    CAS  Google Scholar 

  32. Deria P et al (2014) Beyond post-synthesis modification: evolution of metal–organic frameworks via building block replacement. Chem Soc Rev 43(16):5896–5912

    Article  CAS  PubMed  Google Scholar 

  33. Spitsyna AS et al (2022) Stability of ZIF-8 nanoparticles in most common cell culture media. Molecules 27(10):3240

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Samadi-Maybodi A, Sedighi-Pashaki E (2021) Comprehensive study of loading and release of sodium valproate drug molecule from functionalized SBA-15 with aminopropyl groups through Co-condensation modification method. Mater Chem Phys 257:123622

    Article  CAS  Google Scholar 

  35. Velásquez-Hernández MD (2019) Degradation of ZIF-8 in phosphate buffered saline media. Cryst Eng Comm 21(31):4538–4544

    Article  Google Scholar 

  36. Luzuriaga MA et al (2019) ZIF-8 degrades in cell media, serum, and some—but not all—common laboratory buffers. Supramol Chem 31(8):485–490

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Tanum J et al (2022) Generation of zinc ion-rich surface via in situ growth of ZIF-8 particle: Microorganism immobilization onto fabric surface for prohibit hospital-acquired infection. Chem Eng J 446:137054

    Article  PubMed  PubMed Central  Google Scholar 

  38. Amedi HR, Aghajani M (2017) Aminosilane-functionalized ZIF-8/PEBA mixed matrix membrane for gas separation application. Microporous Mesoporous Mater 247:124–135

    Article  CAS  Google Scholar 

  39. Zhang W et al (2021) Intelligent dual responsive modified ZIF-8 nanoparticles for diagnosis and treatment of osteoarthritis. Mater Des 209:109964

    Article  CAS  Google Scholar 

  40. Bi J et al (2018) Synthesis of folic acid-modified DOX@ ZIF-8 nanoparticles for targeted therapy of liver cancer. J Nanomater. https://doi.org/10.1155/2018/1357812

    Article  Google Scholar 

  41. Hoop M et al (2018) Biocompatibility characteristics of the metal organic framework ZIF-8 for therapeutical applications. Appl Mater Today 11:13–21

    Article  Google Scholar 

  42. Patil-Gadhe A, Pokharkar V (2014) Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. Eur J Pharm Biopharm 88(1):160–168

    Article  CAS  PubMed  Google Scholar 

  43. Becker AL, Indra AK (2023) Oxidative stress in melanoma: beneficial antioxidant and pro-oxidant therapeutic strategies. Cancers 15(11):3038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Obrador E et al (2019) Oxidative stress and antioxidants in the pathophysiology of malignant melanoma. Biol Chem 400(5):589–612

    Article  CAS  PubMed  Google Scholar 

  45. Cannavò SP et al (2019) The role of oxidative stress in the biology of melanoma: a systematic review. Pathol Res Pract 215(1):21–28

    Article  PubMed  Google Scholar 

  46. Khalil I et al (2019) Nanoantioxidants: recent trends in antioxidant delivery applications. Antioxidants 9(1):24

    Article  PubMed  PubMed Central  Google Scholar 

  47. He L et al (2020) Highly bioactive zeolitic imidazolate framework-8–capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke. Sci Adv 6(12):eaay9751

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  48. Dengiz GO et al (2007) Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats. J Pharmacol Sci 105(1):94–102

    Article  CAS  PubMed  Google Scholar 

  49. Khodir AE et al (2014) Montelukast reduces sepsis-induced lung and renal injury in rats. Can J Physiol Pharmacol 92(10):839–847

    Article  CAS  PubMed  Google Scholar 

  50. Tortolini C et al (2018) Metal oxide nanoparticle based electrochemical sensor for total antioxidant capacity (TAC) detection in wine samples. Biosensors 8(4):108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors are grateful for the support of the Research Council of Mazandaran University, Iran.

Author information

Authors and Affiliations

  1. Analytical Division, Faculty of Chemistry, University of Mazandaran, Babolsar, Iran

    Seyedeh Narges Mousavi Kani & Abdolraouf Samadi-Maybodi

  2. Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

    Hossein Najafzadehvarzi

Authors
  1. Seyedeh Narges Mousavi Kani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdolraouf Samadi-Maybodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hossein Najafzadehvarzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ASM, SNMK and HN contributed to study concept and design and development of the protocol and participated in designing the evaluation; ASM and SNMK contributed to analysis and interpretation of data and critically revised the manuscript for important intellectual content; and SNMK drafted the manuscript and contributed to statistical analysis. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Abdolraouf Samadi-Maybodi.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

Not applicable.

Additional information

Handling Editor: Annela M. Seddon.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kani, S.N.M., Samadi-Maybodi, A. & Najafzadehvarzi, H. Cytotoxicity of ZIF-8@APTES-MS on murine melanoma cells. J Mater Sci 59, 3959–3969 (2024). https://doi.org/10.1007/s10853-023-09214-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10853-023-09214-8

Search

Navigation